Clinical trial · Observational
Sequence of Radiation and Targeted Therapy in Brain Metastases
The Optimal Sequence of Intracranial Radiotherapy Compared to Systematic Tyrosine Kinase Inhibitors for Gene-driven Brain Metastases in Targeted Treatment Era
NCT04832672CI-TRIAL-00051089completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators conducted a single institutional, retrospective cohort study to demonstrate the appropriate treatment strategy of upfront intracranial radiotherapy or upfront targeted therapy in patients with brain metastases, including an assessment of its feasibility and toxicity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| The Optimal Sequence of Radiotherapy and Systematic Tyrosine Kinase Inhibitors in Treating Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- The upfront radiotherapy group
- label
- The upfront targeted-therapy group
Primary outcomes (1)
- measure
- Intracranial progression-free survival
- timeFrame
- The interval from the start of initial intracranial treatment to first documented intracranial progression, or date of death from any cause, whichever came first, assessed up to 3 to 5 years
- description
- The survival time of patients before any intracranial progression
Secondary outcomes (2)
- measure
- Overall survival
- timeFrame
- The time from the date of initial intracranial treatment until death from any cause or censored on the last follow-up, whichever came first, assessed up to 3 to 5 years
- description
- The survival time of patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Had histologically proven primary cancer. * Had newly diagnosed brain metastases in contrast-enhanced MRI. * Brain metastases focus should be measurable. * All the patients should safely receive radiotherapy and/or systematic tyrosine kinase inhibitors. * Karnofsky performance score (KPS) ≥60 or KPS ≥40, but only caused by brain metastases. Exclusion Criteria: * Patients with prior intracranial local treatments, such as surgery and radiotherapy without dose prescription in detail * Patients with leptomeningeal metastases at first diagnosis. * Had synchronous or metachronous malignancies that might affect survival. * Had severe systemic diseases, abnormal conditions that might lead to incoordinate behavior during the implementation of clinical measures. * Had incomplete sociodemographic and/or clinicopathologic baseline data
References
Publications (1)
- DERIVEDYang S, Xiao J, Liu Q, Zhang Y, Bi N, Huang X, Chen X, Wang K, Ma Y, Deng L, Wang W, Zhao R, Li J, Yi J, Wang S, Li Y. The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience. Front Oncol. 2021 Oct 14;11:732883. doi: 10.3389/fonc.2021.732883. eCollection 2021. PMID 34722275